A Non-immunological Phospholipid-Dependent Coagulation Inhibitor Associated with IgGλ-Type Multiple Myeloma

American Journal of Hematology

Volumn 75, Issue 1, 2004, Pages 34-39

  Takamiya, Osamu ^a   Machida, Shinichiro ^b   Okuda, Masahiro ^c   Nojima, Junzo ^d   Koreeda, Chikako ^b   Kubara, Katuhiko ^e  

^a SHINSHU UNIVERSITY   (Japan)

^b Iki Public Hospital   (Japan)

^c SYSMEX CORPORATION   (Japan)

^d OSAKA UNIVERSITY HOSPITAL   (Japan)

^e Kubara Clinic   (Japan)

Author keywords

APTT; IgG ; Multiple myeloma; Non immunological coagulation inhibitor; Phospholipid dependent

Indexed keywords

BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING INHIBITOR; CARDIOLIPIN; CHROMOGENIC SUBSTRATE; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN LAMBDA CHAIN; LUPUS ANTICOAGULANT; PEPSIN A; PHOSPHOLIPID; PROTEIN C; PROTHROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; CASE REPORT; CLINICAL FEATURE; COMPLEX FORMATION; CONFORMATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERTENSION; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTHROMBIN TIME;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR XA; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LUPUS COAGULATION INHIBITOR; MIDDLE AGED; MULTIPLE MYELOMA; PEPSIN A; PHOSPHOLIPIDS; PROTEIN ISOFORMS; RECEPTORS, IMMUNOLOGIC;

EID: 0346786464     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10449     Document Type: Article

References (22)

1. Furie B. Acquired coagulation disorders and dysproteinemias. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and thrombosis. Philadelphia: J.B. Lippincott Company; 1987. p 577-581.
2. Robert F, Mignucci M, McCurcy SA, Maldonado N, Lee JY. Hemostatic abnormalities associated with monoclonal gammopathies. Am J Med Sci 1993;306:359-366.
3. Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z. Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 2001;14:401-436.
4. Shinagawa A, Kojima H, Kobayashi T, Kawada K, Nagasawa T. Lupus anticoagulant-like activity observed in a dimeric lambda protein produced by myeloma cells. Int J Hematol 2001;73:526-531.
5. Yasin Z, Quick D, Thiagarajan P, Spoor D, Caraveo J, Palascak J. Light-chain paraproteins with lupus anticoagulant activity. Am J Hematol 1999;62:99-102.
6. O'Kane MJ, Wisdom GB, Desai ZR, Archbold GP. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. J Clin Pathol 1994;47:266-268.
7. Aoki S, Sibata A. Anemia and hemostatic abnormalities associated with multiple myeloma. Nippon Rinsho 1995;53:154-158 (in Japanese).
8. Glaspy JA. Hemostatic abnormalities m multiple myeloma and related disorders. Hematol Oncol Clin North Am 1992;6:1301-1314.
9. Kapadia SB. Multiple myeloma: a clinicopathologic study of 62 consecutively autopsied cases. Medicine (Baltimore) 1980;59:380-392.
10. Sakakura M, Wada H, Watanabe R, Mamamuro M, Okugawa Y, Nakasaki T, et al. Coagulation tests and anti-phospholipid antibodies in patients positive for lupus anticoagulant. Clin Appl Thromb Hemost 2000;6:144-150.
11. Takamiya O. Studies on protein C. 11. Biological and immunological assay of human protein C. J Nara Med Assoc 1984;35:448-459.
12. Alving BM, Barr CF, Johansen LE, Tang DB. Comparison between a one-point dilute phospholipid APTT and the dilute Russell viper venom time for verification of lupus anticoagulants. Thromb Haemost 1992;67:672-678.
13. van den Besselaar AM, Neuteboom J, Bertina RM. Related articles. Effect of synthetic phospholipids on the response of the activated partial thromboplastin time to heparin. Blood Coagul Fibrinolysis 1993;4:895-903.
14. Bock PE, Srinivasan KR, Shore JD. Related articles. Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid metal ion complexes are the activating species. Biochemistry 1981;20:7258-7266.
15. Nojima J, Kitani T, Iwatani Y, Kanakura Y. Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus. Br J Haematol 2001;114:647-654.
16. Saif MW, Allegra CJ, Greenberg B. Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res 2001;10:657-660.
17. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996;47:533-553.
18. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991;66:629-632.
19. Thiagarajan P, Shapiro SS, De Marco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 1980;66:397-405.
20. Bellotti V, Gamba G, Merlini G, Montani N, Bucciarelli E, Stoppini M, et al. Study of three patients with monoclonal gammopathies and "lupus-like" anticoagulants. Br J Haematol 1989;73:221-227.
21. Erntell M, Myhre EB, Kronvall G. Non-immune IgG F(ab′)2 binding to group C and G streptococci is mediated by structures on gamma chains. Scand J Immunol 1985;21:151-157.
22. Fujita K. Immunochemical study of immunoglobulins bound to lactate dehydrogenase. Clin Chem Acta 1997;264:163-176.